Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-11
2011-01-11
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S364000, C514S378000, C514S539000, C548S236000, C548S131000, C548S247000, C560S043000
Reexamination Certificate
active
07868031
ABSTRACT:
The present invention relates to propionamide compounds of formula I for use as antiinflammatory agents:wherein R1, R2and R3are as defined herein and pharmaceutically acceptable salts thereof. The invention also relates to methods of using the compounds of formula I and pharmaceutical compositions comprising the compounds of formula I.
REFERENCES:
patent: 6245804 (2001-06-01), Lehmann et al.
patent: 6323199 (2001-11-01), Lehmann et al.
patent: 6344454 (2002-02-01), Lehmann et al.
patent: 6380207 (2002-04-01), Coghlan et al.
patent: 6903215 (2005-06-01), Betageri et al.
patent: 2002/0077356 (2002-06-01), Jaroch et al.
patent: 2003/0232823 (2003-12-01), Betageri et al.
patent: 2004/0029932 (2004-02-01), Bekkali et al.
patent: 2004/0224992 (2004-11-01), Cywin et al.
patent: 2004/0254249 (2004-12-01), Jaroch et al.
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, pp. 205-213.
Schacke et al. Pharmacology & Therapeutics 2002, 96, 23-43.
Tischner et al. Molecular and Cellular Endocrinology 2007, 275, 62-70.
Sorrells et al. Brain, Behavior, and Immunity 2007, 21, 259-272.
DorwaId, F. Zaragoza. Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design, Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA, 2005, Preface.
Kuzmich et al. Bioorganic & Medicinal Chemistry Letters 2007, 17, 5025-5031.
Wermuth, C.G. “Molecular Variations Based on Isoteric Replacements” in “The Practice of Medicinal Chemistry” 1996, Academic Press Limited, pp. 203-237.
Betageri et al. Biorganic & Medicinal Chemistry Letters 2005, 15, 4761-4769.
Patani et al. Chem. Rev. 1996, 96, 3147-3176.
Mueller, M. M. European Journal of Cancer 2006, 42, 735-744.
Lee et al. Critical Reviews in Oncology/Hematology 2008, 66, 208-217.
Golub et al., Science, vol. 286, Oct. 15, 1999, pp. 531-537.
Giron, D. J. Therm. Anal. Cal. 2001, 64, pp. 37-60.
Giron, D. J. Therm. Anal. Cal. 2002, 68, pp. 335-357.
B. Rodriquez-Spong et al. Advanced Drug Delivery Reviews, 2004, 56, pp. 241-274.
Souillac, et al., Characterization of Delivery Systems, Differential Scanning Calorimetry, pp. 217-218 (in Encyclopedia of Controlled Drug Delivery, 1999, John Wiley & Sons, pp. 212-227).
Heck, S., et. al. “A Distinct Modulating Domain in Glucocorticoid Receptor Monomers in the Repression of Activity of the Transcription Factor AP-1,”EMBO J. (1994) vol. 13 (17) pp. 4087-4095.
Prakash, G.K.S., et. al., “Perfluoroalkylation with Organosilicon Reagents,”Chem. Rev. (1997) 97, pp. 757-786.
Ramaiah, P. et. al., Direct Trifluoromethylation of a-Keto Esters to b,b,b-Trifluorolactic Acid Derivatives Using Trifluoromethyltrimethylsilane,Synlett(1991) vol. 9, pp. 643-644.
Reichardt, H. M., et. al., “DNA Binding of the Glucocorticoid Receptor is not Essential for Survival,”Cell(1998) vol. 93, pp. 531-541.
Tronche, F., et. al., “Genetic Dissection of Glucocorticoid Receptor Function in Mice,”Curr. Opin. Genet. Dev. (1998) vol. 8, pp. 532-538.
Gong Leyi
O'Yang Counde
Tan Yun-chou
Anderson Rebecca L
Coughlin Matthew P
Johnston George W.
Megerditchian Samuel H.
Roche Palo Alto LLC
LandOfFree
Propionamide compounds as antiinflammatory agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Propionamide compounds as antiinflammatory agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Propionamide compounds as antiinflammatory agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2707121